93 related articles for article (PubMed ID: 6352833)
1. [Effect of prostaglandin I2 derivative infusion during experimental cardiopulmonary bypass].
Matsukura H; Takeda H; Uzawa S; Sakai K; Kawakami T; Tanabe T
Nihon Kyobu Geka Gakkai Zasshi; 1983 Jun; 31(6):871-5. PubMed ID: 6352833
[No Abstract] [Full Text] [Related]
2. [Effects of prostaglandin I2 infusion during experimental cardiopulmonary bypass (author's transl)].
Matsukura H; Takeda H; Kawakami T; Tanabe T
Nihon Kyobu Geka Gakkai Zasshi; 1982 Feb; 30(2):164-71. PubMed ID: 7047654
[No Abstract] [Full Text] [Related]
3. [Experimental studies on platelet preservation with prostaglandin I2 and its derivative (OP-41483) during cardiopulmonary bypass].
Takeda H
Hokkaido Igaku Zasshi; 1989 Jul; 64(4):500-11. PubMed ID: 2511131
[TBL] [Abstract][Full Text] [Related]
4. The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level.
Sinzinger H; Steurer G; Fitscha P; Kraupp O
Prog Clin Biol Res; 1987; 242():19-23. PubMed ID: 2444986
[No Abstract] [Full Text] [Related]
5. [Experimental study upon platelet preservation by prostaglandin I2 during extracorporeal circulation].
Osada H; Kawada T; Hoson M; Funaki S; Arase K; Masaki H; Taira Y; Kuwahara M; Noguchi T
Nihon Kyobu Geka Gakkai Zasshi; 1984 Oct; 32(10):1795-803. PubMed ID: 6394659
[No Abstract] [Full Text] [Related]
6. [Evaluation of prostaglandin I2 and its derivative in extracorporeal circulation].
Takeda H; Matsukura H; Kawakami T; Tanabe T
Kyobu Geka; 1983 Jun; 36(6):479-84. PubMed ID: 6355587
[No Abstract] [Full Text] [Related]
7. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
Coppe D; Sobel M; Seamans L; Levine F; Salzman E
J Thorac Cardiovasc Surg; 1981 Feb; 81(2):274-8. PubMed ID: 7005550
[TBL] [Abstract][Full Text] [Related]
8. Platelet preservation during cardiopulmonary bypass (CPB) with prostaglandin (PGE1) and prostacyclin (PGI2).
van den Dungen JJ; Velders AJ; Karliczek GF; Homan van der Heide JN; Wildevuur CR
Trans Am Soc Artif Intern Organs; 1980; 26():481-6. PubMed ID: 7018057
[No Abstract] [Full Text] [Related]
9. Application of a new prostaglandin I2 analogue (APS-306) on cardiopulmonary bypass.
Takahama T; Kanai F; Iizuka I; Hiraishi M; Yamazaki Z; Idezuki Y; Sudo K; Asano K; Morioka M; Kazama M
Trans Am Soc Artif Intern Organs; 1984; 30():44-8. PubMed ID: 6398549
[No Abstract] [Full Text] [Related]
10. Preservation of platelets and their function in prolonged cardiopulmonary bypass using prostacyclin.
Koshal A; Krausz MM; Utsunomiya T; Hechtman HB; Collins JJ; Cohn LH
Circulation; 1981 Aug; 64(2 Pt 2):II44-8. PubMed ID: 7018736
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of platelet lysis, platelet consumption on oxygenator, and stabilization of platelet membrane with prostacyclin and ibuprofen during cardiopulmonary bypass surgery in dogs.
Dewanjee MK; Vogel SR; Peterson KA; Lim MF; Kaye MP
Trans Am Soc Artif Intern Organs; 1981; 27():197-202. PubMed ID: 7036497
[No Abstract] [Full Text] [Related]
12. Prevention by a stable prostacyclin analogue, 7-oxoprostaglandin I2 of the platelet loss during experimental cardiopulmonary bypass.
Juhász-Nagy S; Kékesi V; Sótonyi P; Moravcsik G; Kovács G
Acta Chir Hung; 1988; 29(3):251-61. PubMed ID: 3071058
[TBL] [Abstract][Full Text] [Related]
13. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981.
Vane JR
J Endocrinol; 1982 Nov; 95(2):3P-43P. PubMed ID: 6816886
[No Abstract] [Full Text] [Related]
14. Epoprostenol now the focus of numerous clinical trials.
Check WA
JAMA; 1981 Jun; 245(24):2481-3. PubMed ID: 7014954
[No Abstract] [Full Text] [Related]
15. Heparin, cardiopulmonary bypass, and platelet dysfunction.
Muriithi EW; Belcher PR
Artif Organs; 2006 Jun; 30(6):488-9. PubMed ID: 16734602
[No Abstract] [Full Text] [Related]
16. A comparative study of prostacyclin infusion given before and during cardiopulmonary bypass to assess the first pass effect of the circuit on platelet number and function.
Jestice HK; Humphreys JE; English TA; Hoggarth CE; Wells FC
Eur J Cardiothorac Surg; 1990; 4(1):40-4. PubMed ID: 2106334
[TBL] [Abstract][Full Text] [Related]
17. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
[TBL] [Abstract][Full Text] [Related]
18. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
Jaschonek K; Renn W; Weisenberger H
Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
[No Abstract] [Full Text] [Related]
19. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue.
Huddleston CB; Hammon JW; Wareing TH; Lupinetti FM; Clanton JA; Collins JC; Bender HW
J Thorac Cardiovasc Surg; 1985 Feb; 89(2):190-5. PubMed ID: 2578591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
